Spots Global Cancer Trial Database for Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
Official Title: A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies
Study ID: NCT00710528
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
Detailed Description: A Phase 1, sequential dose escalation followed by cohort expansion study of CAL-101, an oral inhibitor of PI3K delta, in patients with relapsed or refractory CLL, select B-cell NHL and AML.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford Cancer Center, Palo Alto, California, United States
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Washington University School of Medicine, St. Louis, Missouri, United States
Weill Medical College of Cornell, New York, New York, United States
The Ohio State University Medical Center, Columbus, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
University of Wisconsin, Madison, Wisconsin, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
